Upamostat: a serine protease inhibitor for antiviral, gastrointestinal and anticancer indications
Expert Opin Investig Drugs. 2023 Nov 16. doi: 10.1080/13543784.2023.2284385. Online ahead of print.ABSTRACTINTRODUCTION: Serine proteases are involved in many normal metabolic processes but also contribute to diseases of several organ systems, including viral and gastrointestinal diseases and oncology. Upamostat is an orally bioavailable prodrug of WX-UK1, which is most active against trypsins and closely related enzymes.AREAS COVERED: Research over the past two decades suggests several diseases in the three areas noted above which upamostat may be active. Upamostat has been studied clinically against several cancers and f...
Source: Expert Opinion on Investigational Drugs - November 16, 2023 Category: Drugs & Pharmacology Authors: T F Plasse R Fathi C Fehrmann G A McComsey Source Type: research

First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor xa and factor IIa
CONCLUSION: SAR107375 exhibits good safety and tolerability, predictable pharmacokinetics and pharmacodynamics.PMID:37955047 | DOI:10.1080/13543784.2023.2283024 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - November 13, 2023 Category: Drugs & Pharmacology Authors: Shuanzhi Wu Tenghua Wang Jieyun Li Zhixin Zhang Chen Li Shuangshuang Xiao Jin He Xuan Wang Zhiqin Hu Xiaole Wang Sichao Zheng Xintong Liang Guiying Chen Yongmei Li Xianbo Li Yaoxuan Zhan Qinwen Zou Hongliang Jiang Qingshan Zheng Li Ban Haiyan Liu Yi Fang Source Type: research

Retatrutide showing promise in obesity (and type 2 diabetes)
Expert Opin Investig Drugs. 2023 Nov 10. doi: 10.1080/13543784.2023.2283020. Online ahead of print.ABSTRACTINTRODUCTION: Obesity is a major risk factor for cardiovascular disease, diabetes, osteoarthritis, and some cancers. Retatrutide stimulates Glucagon-like peptide 1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP) receptors, and glucagon receptors, and is being developed for the treatment of obesity and type 2 diabetes.AREAS COVERED: A phase 2 clinical trial of retatrutide (LY3437943) in the treatment of obesity. The primary end point was percentage change in weight from baseline to 24 weeks, which ranged fr...
Source: Expert Opinion on Investigational Drugs - November 10, 2023 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research

Developments and challenges for new and emergent preparations for male hypogonadism treatment
Expert Opin Investig Drugs. 2023 Nov 9:1-14. doi: 10.1080/13543784.2023.2276760. Online ahead of print.ABSTRACTINTRODUCTION: The specific role of testosterone (T) replacement therapy in patients with late onset hypogonadism is still conflicting. Several available preparations have been developed to restore either fertility and normal testosterone (T) levels (secondary hypogonadism) or just T levels (primary hypogonadism).AREAS COVERED: Advantages and limitations related to available new treatments will be discussed in detail. In addition, possible news related to preparations in the pipeline will be discussed.EXPERT OPINIO...
Source: Expert Opinion on Investigational Drugs - November 9, 2023 Category: Drugs & Pharmacology Authors: Giovanni Corona Clotilde Sparano Giulia Rastrelli Linda Vignozzi Mario Maggi Source Type: research

Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review
Expert Opin Investig Drugs. 2023 Nov 6:1-7. doi: 10.1080/13543784.2023.2279146. Online ahead of print.ABSTRACTINTRODUCTION: Glaucoma is a leading cause of blindness with intraocular pressure (IOP) as the only known modifiable risk factor. Prostaglandin FP receptor agonists are the first-line medical treatment for glaucoma and ocular hypertension. Despite their efficacy, their IOP lowering effect may be insufficient requiring second agents, and poor patient compliance to medical therapy may preclude their full effect.AREAS COVERED: This literature review examines the novel FP receptor drugs and drug delivery devices in clin...
Source: Expert Opinion on Investigational Drugs - November 6, 2023 Category: Drugs & Pharmacology Authors: Sophia Moshegov Nathan Mitchell Kerr Source Type: research

Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review
Expert Opin Investig Drugs. 2023 Nov 6. doi: 10.1080/13543784.2023.2279146. Online ahead of print.ABSTRACTINTRODUCTION: Glaucoma is a leading cause of blindness with intraocular pressure (IOP) as the only known modifiable risk factor. Prostaglandin FP receptor agonists are the first line medical treatment for glaucoma and ocular hypertension. Despite their efficacy, their IOP lowering effect may be insufficient requiring second agents, and poor patient compliance to medical therapy may preclude their full effect.AREAS COVERED: This literature review examines the novel FP receptor drugs and drug delivery devices in clinical...
Source: Expert Opinion on Investigational Drugs - November 6, 2023 Category: Drugs & Pharmacology Authors: Sophia Moshegov Nathan Mitchell Kerr Source Type: research